Re: Thoughts on ZCC
in response to
by
posted on
Sep 09, 2021 12:10PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Toinv, yes Sanjay Lakhotia came to Zenith with Julie Cherington. He had worked for her at Pathway where she was CEO. I have noticed that she has been appointed to the BoD's of a few biotechs in the recent past. Can't say the same for Don, probably speaks to relative quality of business talent.